Categories: Health

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

 | Source: PolyPid Ltd.

PETACH TIKVA, Israel, June 06, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will host a conference call and webcast to report topline data for the SHIELD II Phase 3 trial, evaluating D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery, on Monday, June 9, at 8:30 a.m. ET.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call.

Conference Call Dial-In & Webcast Information:

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Contacts:
PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com

Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com

GlobeNews Wire

Recent Posts

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch

GlucoModicum Reports Positive Clinical Results with its Needle-Free CGM and Advances Toward Market Launch Comprehensive…

15 hours ago

BioVersys and Shionogi Enter Into Global Research Collaboration For Broad-Spectrum Non-Tuberculous Mycobacteria (NTM) Clinical Candidate

July 02, 2025 01:00 ET  | Source: BioVersys Ad hoc announcement pursuant to Art. 53…

15 hours ago

A New Landmark for Fun: Timezone’s Largest Flagship Venue Opens at Inorbit Mall Malad

Timezone, the leading brand in family and social entertainment from Australia, opens its largest, most…

15 hours ago

4SidesPlay Debuts as South India’s First Language-Driven OTT Platform

A New Era of Regional Digital Entertainment Begins with a Dedicated Platform for Telugu, Tamil,…

15 hours ago

100 Years of DEKRA: Safety in a Changing World

Expert Organization Celebrates Centennial STUTTGART, Germany, June 30, 2025 /PRNewswire/ -- Today DEKRA celebrates its…

15 hours ago

Oman Air joins oneworld alliance

Oman Air becomes 15th alliance member oneworld customers now have access to Oman Air's route…

15 hours ago